3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
4
Neoplasms
3
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Stomatitis
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oncology Patients Receiving Chemotherapy
1
Mucositis
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Burkitt Lymphoma
1
Interventions
tisagenlecleucel
8
Cyclophosphamide
7
fludarabine
5
blinatumomab
5
aflibercept
4
ibrutinib
2
epratuzumab
2
Vincristine
2
Radioimmunodetection
2
Methotrexate
2
MLN 8237
2
Inotuzumab Ozogamicin
2
Dexamethasone
2
tocilizumab
1
tafasitamab
1
siltuximab
1
sepantronium
1
ruxolitinib
1
relatlimab
1
pembrolizumab
1
pegaspargase
1
ontuxizumab
1
obinutuzumab
1
loncastuximab tesirine
1
forodesine
1
fludarabine phosphate
1
fiu protein, E coli
1
exatecan
1
brexucabtagene autoleucel
1
asparaginase erwinia chrysanthemi recombinant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Burkitt Lymphoma
×
Diphenhydramine
×
Clear all
NCT07570173
2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled